Azelis Group (AZE) H2 2024 earnings summary

Executive summary

• Revenue for 2024 increased by 2.6% in constant currency to EUR 4.2 billion, with organic growth turning positive in H2 after a decline in H1.

• Gross profit reached EUR 1.0 billion, with a 77 basis point increase in gross margin to 24.5%, driven by positive mix effects and portfolio optimization.

• Adjusted EBITDA was EUR 471 million, up 0.9% year-over-year, with a stable margin of 11.2% despite cost inflation.

• Net profit was stable at EUR 189.5 million, with an effective tax rate of 26%.

• Eight acquisitions were completed in 2024, adding over EUR 140 million in revenue and supporting strategic expansion.

Financial highlights

• Q4 revenue grew 4.3% year-over-year, with 1.8% organic growth; full-year organic revenue declined 1.1% but rebounded in H2.

• Gross profit for Q4 grew 10.4% year-over-year; full-year gross profit up 4.8%.

• Adjusted EBITDA for Q4 increased 11.4%, reversing earlier declines; full-year adjusted EBITDA margin remained at 11.2%.

• Free cash flow was EUR 341.8 million, down 43.1% due to higher working capital investments as demand improved.

• Net working capital to revenue rose to 15.9% at year-end, reflecting inventory build-up for anticipated demand.

Outlook and guidance

• Order book for Q1 2025 is developing positively, with expectations for continued organic growth and gross profit improvement.

• Positive momentum in the Americas, especially the U.S., is expected to persist, though volatility remains.

• Management expects continued recovery in end markets, with gradual improvement in market sentiment.

• Medium-term outlook remains attractive for specialty chemicals and ingredients distribution, with further value to be unlocked through strategy execution.

• Gross margin may fluctuate depending on segment mix, with industrials typically lower margin than life sciences.